The abstract submission is now open
Abstract submission deadlines
Deadline |
Date and time |
|---|---|
Abstracts |
8 April 2025, 21:00hrs CEST |
|
Late-breaking abstracts (LBA) |
5 June 2025, 21:00hrs CEST |
Abstract submission categories
- Colon cancer
- Hepatocellular and non-biliary liver cancer
- Rare GI cancers (GEP-NETs, endocrine pancreatic, duodenal cancer, anal cancer, etc)
- Rectal cancer
- Upper digestive – Biliary, ampullary and pancreatic cancer
- Upper digestive – Esophageal and gastric cancers
- Miscellaneous
Late-breaking abstracts
Late-breaking abstracts may be submitted for high quality, new research findings from prospective interventional clinical trials or observational series (large real world data sets) or novel technologies with major implications for clinical practice and/or understanding and targeting of disease processes.
The final late-breaking abstract deadline of 5 June 2025 is under no circumstances to be considered as an extension of the general submission deadline.
Trial in Progress abstracts (TiP)
Trial in Progress (TiP) abstracts in all phases of clinical research (phases I to III) may be submitted to the ESMO Gastrointestinal Cancers Congress 2025.
It is expected that abstracts submitted as Trial in Progress are ongoing trials that have not reached any protocol-specified endpoints for analysis.
Outcome notifications
Outcome notifications are expected to be made available to first authors and submitters by end-April.
Outcome notifications of accepted full LBAs are expected to be made available to first authors and submitters by 10 June 2025.
Information for presenters
Detailed instructions for the preparation of slide presentations and/or posters will be made available by end-April in the section “Information for Presenters”.
Abstract presenter registration
The presenting author or the designated replacement presenter must be registered by 11 June 2025 (16 June for Late-breaking abstracts only). Should the Presenter (or designated replacement presenter) not be registered by the given deadline, the abstract will be excluded from presentation in the ESMO Gastrointestinal Cancers 2025 programme, and removed from the online programme and publication in the ESMO Gastrointestinal Cancers 2025 Abstract Book.
Presentation and publication of accepted abstracts
The ESMO Gastrointestinal Cancers 2025 Scientific Committee will select abstracts for presentation during the Congress based on the following possibilities:
- Proffered Paper – Oral presentations by authors presenting original data of superior quality, followed by expert discussion and perspectives.
- Mini Oral – Short oral presentations by authors presenting data of good quality, followed by expert discussion and perspectives.
- Poster – Paper poster presentation for review and discussion onsite. Presenting authors must attend the Congress in person to represent their work. Preparation of an ePoster is also mandatory for inclusion in the Congress Virtual Platform and onsite digital screens.
- E-Poster – Electronic poster in PDF format for inclusion in the Congress Virtual Platform and onsite digital screens. Presenting authors of ePosters are not required to attend the Congress in person to represent their work. Paper posters are not to be prepared, and poster boards will not be provided.
All accepted abstracts will be published online only in the ESMO Gastrointestinal Cancers 2025 Abstract Book, a supplement to the official ESMO journal, Annals of Oncology.
Publication schedule for accepted abstracts
Details regarding the publication of accepted abstracts are available here.
ESMO Merit Travel Grant
A restricted number of ESMO Merit Travel Grants to the ESMO Gastrointestinal Cancers Congress 2025 are available, upon application, to first author (= presenter) who submit abstracts considered to be deserving of recognition. Candidates must be ESMO Members under the age of 40. Selection will be made by the ESMO Gastrointestinal Cancers Congress 2025 Scientific Committee on a competitive basis from among the accepted abstracts.